訂正

DOI Web Site

書誌事項

タイトル別名
  • Erratum to : Evaluation of Appropriate Use of SGLT2-inhibitors with Evaluation of Adopted Medicines and Application of Criterion

抄録

<p>第43巻　第2号　93頁　引用文献　8）を次の通り訂正いたします</p><p>誤：8）Lee S, Monz BU, Clemens A, Brueckmann M, Lip GYH, Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a crosssectional analysis using the General Practice Research Database, BMJ Open, 2012, 2, e001768. doi:10.1136/bmjopen-2016-013774.</p><p>正：8）Lee S, Monz BU, Clemens A, Brueckmann M, Lip GYH, Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a crosssectional analysis using the General Practice Research Database, BMJ Open, 2012, 2, e001768. doi:10.1136/bmjopen-2012-001768.</p><p>　下線が訂正した部分</p>

収録刊行物

  • 医療薬学

    医療薬学 43 (4), erratum_4-erratum_4, 2017

    一般社団法人日本医療薬学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ